These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

952 related articles for article (PubMed ID: 14695756)

  • 1. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
    Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
    Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human prostate cancer progression models and therapeutic intervention.
    Chung LW; Kao C; Sikes RA; Zhau HE
    Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis.
    Matsubara S; Wada Y; Gardner TA; Egawa M; Park MS; Hsieh CL; Zhau HE; Kao C; Kamidono S; Gillenwater JY; Chung LW
    Cancer Res; 2001 Aug; 61(16):6012-9. PubMed ID: 11507044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
    Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
    Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
    Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
    J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models.
    Ko SC; Cheon J; Kao C; Gotoh A; Shirakawa T; Sikes RA; Karsenty G; Chung LW
    Cancer Res; 1996 Oct; 56(20):4614-9. PubMed ID: 8840973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
    Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
    Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer.
    Hall SJ; Canfield SE; Yan Y; Hassen W; Selleck WA; Chen SH
    Gene Ther; 2002 Apr; 9(8):511-7. PubMed ID: 11948376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transcriptional targeting of virus-mediated gene transfer by the human hexokinase II promoter.
    Määttä AM; Korja S; Venhoranta H; Hakkarainen T; Pirinen E; Heikkinen S; Pellinen R; Mäkinen K; Wahlfors J
    Int J Mol Med; 2006 Nov; 18(5):901-8. PubMed ID: 17016620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter.
    Pramudji C; Shimura S; Ebara S; Yang G; Wang J; Ren C; Yuan Y; Tahir SA; Timme TL; Thompson TC
    Clin Cancer Res; 2001 Dec; 7(12):4272-9. PubMed ID: 11751529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo suppression of osteosarcoma pulmonary metastasis with intravenous osteocalcin promoter-based toxic gene therapy.
    Shirakawa T; Ko SC; Gardner TA; Cheon J; Miyamoto T; Gotoh A; Chung LW; Kao C
    Cancer Gene Ther; 1998; 5(5):274-80. PubMed ID: 9824046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer.
    Hall SJ; Mutchnik SE; Yang G; Timme TL; Nasu Y; Bangma CH; Woo SL; Shaker M; Thompson TC
    Cancer Gene Ther; 1999; 6(1):54-63. PubMed ID: 10078964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters.
    Majumdar AS; Hughes DE; Lichtsteiner SP; Wang Z; Lebkowski JS; Vasserot AP
    Gene Ther; 2001 Apr; 8(7):568-78. PubMed ID: 11319624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATRA enhances bystander effect of suicide gene therapy in the treatment of prostate cancer.
    Chen W; Yan C; Hou J; Pu J; Ouyang J; Wen D
    Urol Oncol; 2008; 26(4):397-405. PubMed ID: 18367126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
    Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
    Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
    Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
    J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
    Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
    Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the Cre recombinase/loxP system further enhances antitumor effects in cell type-specific gene therapy against carcinoembryonic antigen-producing cancer.
    Kijima T; Osaki T; Nishino K; Kumagai T; Funakoshi T; Goto H; Tachibana I; Tanio Y; Kishimoto T
    Cancer Res; 1999 Oct; 59(19):4906-11. PubMed ID: 10519403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The animal research of recombinant adenovirus controlled by human telomerase reverse transcriptase promoter in the treatment of human prostate cancer].
    Zhang Y; Qi JC; Lian WF; Cai WQ; Li W; Liu KL
    Zhonghua Wai Ke Za Zhi; 2006 Sep; 44(18):1252-5. PubMed ID: 17147886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of human chorionic gonadotropin subunit-beta promoter-based toxic gene therapy for testicular cancer.
    Shirakawa T; Gotoh A; Zhang Z; Kao C; Chung LW; Gardner TA
    Urology; 2004 Mar; 63(3):613-8. PubMed ID: 15028478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.